3min chapter

VJHemOnc Podcast cover image

Post-ASH CLL highlights: BTK inhibitors & degraders, bispecific antibodies, & more!

VJHemOnc Podcast

CHAPTER

Exploring Novel Agents in CLL Treatment: Bispecific Antibodies and BCL2 Inhibitors

This chapter delves into innovative therapies for Chronic Lymphocytic Leukemia, particularly bispecific antibodies and BCL2 inhibitors. It presents the promising results from the EPCOR CLL1 trial and emphasizes strategies for managing treatment-related complications.

00:00

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode